IP Library Granted Patent US 11,564,600
Granted Patent B2
US 11,564,600 · App. 17/742,124 · Granted Jan 31, 2023

Systems and methods for analyzing, interpreting, and acting on continuous glucose monitoring data

Inventors: Shiping Liu (Columbia, MD); Mansur Shomali (Columbia, MD); Abhimanyu Kumbara (Columbia, MD); Anand Iyer (Columbia, MD); Malinda Peeples (Columbia, MD); Michelle Dugas (Columbia, MD); Kenyon Crowley (Columbia, MD); Guodong Gao (Columbia, MD)
Assignee: Welldoc, Inc.
A61B5/14532A61B5/1118A61B5/48A61B5/7264A61B5/7267A61B5/7275A61B5/7282A61B5/7475G06N20/00G16H10/40G16H20/00G16H50/30A61B5/0022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,564,600
App. No.
17/742,124
Granted
Jan 31, 2023
Kind
B2
Abstract

Methods and devices include automated coaching for management of glucose states by receiving a user's glucose levels using a continuous glucose monitoring (CGM) device, determining a time in range (TIR) value, determining a TIR state, receiving a glucose variability (GV) value, determining a GV state, determining a starting state based on the TIR state and the GV state, determining that the starting state corresponds to a non-ideal state, generating an optimized pathway to reach an ideal state based on one or more account vectors such as addressing self-management behavior including food, activity, and medication use. The optimized pathway may further be based on computer detection and classification of significant events of interest over time.

Claims (59)

1. A computer-implemented method for managing glucose states of a user, the method comprising:

receiving a plurality of optimization profiles for reaching an ideal state from a non-ideal state, the ideal state corresponding to a first time in range (TIR) state and a first glucose variability (GV) state and the non-ideal state comprising at least one of a second TIR state or a second GV state, wherein the first TIR state is above a threshold TIR value and a second TIR state is below the threshold TIR value;

determining a current TIR state based on a TIR value of the user's glucose level over a first period of time, wherein the TIR value is based on an amount of time the user's glucose level is within a threshold band over a base time period and the current TIR state is one of a first current TIR state or a second current TIR state;

determining a current GV state based on a GV value associated with the user's glucose level, wherein the GV value indicates a standard deviation (SD) of glucose levels or a coefficient of variance (CV), wherein the CV is variability of the user's glucose level in view of a standard deviation of the glucose level over the base time period;

receiving one or more user vectors for the user;

identifying one of the optimization profiles based on the one or more user vectors and one or more user attributes;

identifying an optimized pathway based on the identified optimization profile, the current TIR state, and the current GV state, the optimized pathway comprising one or more adjustments to the one or more user vectors, wherein the one or more adjustments comprise a medication adjustment, a food consumption adjustment, or an exercise value, wherein:

the optimized pathway comprises a user vector change based on the current TIR state and the current GV state;

the user vector change is further based on user attributes, wherein the user attributes comprise a medical attribute, a user preference, a metabolic attribute, or a user demographic;

the optimized pathway is further based on a habit index score of the user, determined based on a cohort of users with one or more user attributes in common with the user; and

providing the optimized pathway to the user.

2. The method of claim 1 , wherein each of the plurality of optimization profiles comprise a different combination of a plurality of user vectors and a plurality of user attributes.

3. The method of claim 2 , wherein the plurality of optimization profiles are each associated with a plurality of optimized pathways, each of the plurality of optimized pathways being identified based on one or more of a potential TIR state or a potential GV state.

4. The method of claim 1 , further comprising:

receiving updated glucose levels over a second period of time;

identifying an updated optimized pathway to reach the ideal state based on the updated glucose levels, the updated optimized pathway comprising insulin intake information; and

providing the updated optimized pathway to the user.

5. The method of claim 1 , wherein the optimized pathway is provided to the user via a graphical user interface.

6. The method of claim 1 , wherein the optimized pathway is provided as a machine learning model output and wherein the machine learning model is trained using one of a supervised learning, unsupervised learning, or semi-supervised learning.

7. The method of claim 1 , further comprising receiving the user attributes from a user input or a user profile.

8. The method of claim 1 , wherein the CV value is determined by dividing the standard deviation of the glucose level by a mean of the glucose level over the base time period.

9. The method of claim 1 , wherein the user's glucose levels are determined by a continuous glucose monitoring (CGM) device configured to obtain bodily fluid via a skin penetrating component.

10. The method of claim 9 , wherein the CGM device is configured to determine the user's glucose levels by sensing a concentration of analytes within the obtained bodily fluid.

11. A system for managing glucose states of a user, the system comprising:

at least one memory storing instructions;

a continuous glucose monitoring (CGM) device configured to obtain bodily fluid via a skin penetrating component; and

at least one processor executing the instructions to perform operations, the operations comprising:

receiving a plurality of optimization profiles for reaching an ideal state from a non-ideal state, the ideal state corresponding to a first time in range (TIR) state and a first glucose variability (GV) state and the non-ideal state comprising at least one of a second TIR state or a second GV state, wherein the first TIR state is above a threshold TIR value and a second TIR state is below the threshold TIR value;

determining a current TIR state based on a TIR value of the user's glucose level over a first period of time, wherein the TIR value is based on an amount of time the user's glucose level is within a threshold band over a base time period and the current TIR state is one of a first current TIR state or a second current TIR state;

determining a current GV state based on a GV value associated with the user's glucose level, wherein the GV value indicates a standard deviation (SD) of glucose levels or a coefficient of variance (CV), wherein the CV is variability of the user's glucose level in view of a standard deviation of the glucose level over the base time period;

receiving one or more user vectors for the user;

identifying one of the optimization profiles based on the one or more user vectors and one or more user attributes;

identifying an optimized pathway based on the identified optimization profile, the current TIR state, and the current GV state, the optimized pathway comprising one or more adjustments to the one or more user vectors, wherein the one or more adjustments comprise a medication adjustment, a food consumption adjustment, or an exercise value, wherein:

the optimized pathway comprises a user vector change based on the current TIR state and the current GV state;

the user vector change is further based on user attributes, wherein the user attributes comprise a medical attribute, a user preference, a metabolic attribute, or a user demographic;

the optimized pathway is further based on a habit index score of the user, determined based on a cohort of users with one or more user attributes in common with the user; and

providing the optimized pathway to the user.

12. The system of claim 11 , wherein each of the plurality of optimization profiles comprise a different combination of a plurality of user vectors and a plurality of user attributes.

13. The system of claim 12 , wherein the plurality of optimization profiles are each associated with a plurality of optimized pathways, each of the plurality of optimized pathways being identified based on one or more of a potential TIR state or a potential GV state.

14. The system of claim 11 , wherein the processor is further configured to:

receive updated glucose levels over a second period of time;

identify an updated optimized pathway to reach the ideal state based on the updated glucose levels, the updated optimized pathway comprising insulin intake information; and

provide the updated optimized pathway to the user.

15. The system of claim 11 , wherein the optimized pathway is provided to the user via a graphical user interface.

16. The system of claim 11 , wherein the optimized pathway is provided as a machine learning model output and wherein the machine learning model is trained using one of a supervised learning, unsupervised learning, or semi-supervised learning.

17. The system of claim 11 , wherein the user attributes are obtained from a user input or a user profile.

18. The system of claim 11 , wherein the CV value is determined by dividing the standard deviation of the glucose level by a mean of the glucose level over the base time period.

19. The system of claim 18 , wherein the CGM device is configured to determine the user's glucose levels by sensing a concentration of analytes within the obtained bodily fluid.

20. A non-transitory computer-readable medium storing instructions that, when executed by a processor, cause the processor to perform operations, the operations comprising:

receiving a plurality of optimization profiles for reaching an ideal state from a non-ideal state, the ideal state corresponding to a first time in range (TIR) state and a first glucose variability (GV) state and the non-ideal state comprising at least one of a second TIR state or a second GV state, wherein the first TIR state is above a threshold TIR value and a second TIR state is below the threshold TIR value;

determining a current TIR state based on a TIR value of the user's glucose level over a first period of time, wherein the TIR value is based on an amount of time the user's glucose level is within a threshold band over a base time period and the current TIR state is one of a first current TIR state or a second current TIR state;

determining a current GV state based on a GV value associated with the user's glucose level, wherein the GV value indicates a standard deviation (SD) of glucose levels or a coefficient of variance (CV), wherein the CV is variability of the user's glucose level in view of a standard deviation of the glucose level over the base time period;

receiving one or more user vectors for the user;

identifying one of the optimization profiles based on the one or more user vectors and one or more user attributes;

identifying an optimized pathway based on the identified optimization profile, the current TIR state, and the current GV state, the optimized pathway comprising one or more adjustments to the one or more user vectors, wherein the one or more adjustments comprise a medication adjustment, a food consumption adjustment, or an exercise value, wherein:

the optimized pathway comprises a user vector change based on the current TIR state and the current GV state;

the user vector change is further based on user attributes, wherein the user attributes comprise a medical attribute, a user preference, a metabolic attribute, or a user demographic;

the optimized pathway is further based on a habit index score of the user, determined based on a cohort of users with one or more user attributes in common with the user; and

providing the optimized pathway to the user.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2022
From: LIU, SHIPING; SHOMALI, MANSUR; KUMBARA, ABHIMANYU; IYER, ANAND; PEEPLES, MALINDA; DUGAS, MICHELLE; CROWLEY, KENYON; GAO, GUODONG
To: WELLDOC, INC.
Reel/Frame 059954/0923 →
Continuity (6)
Continuation 17474807 · Sep 14, 2021
Continuation 17206858 · Mar 19, 2021
Provisional Application 63135818 · Jan 11, 2021
Provisional Application 62992385 · Mar 20, 2020
Provisional Application 62992409 · Mar 20, 2020
Related Publication 20220265179A1 · Aug 25, 2022
Cited By (1)
US 12,639,394